news
Retatrutide shows strong weight loss for type 2 diabetes
The Lancet published findings from the TRIUMPH-2 study on retatrutide, a triple-agonist (GLP-1, GIP, glucagon) for people with obesity and type 2 diabetes. The phase 3 trial showed superior weight-lowering effects, challenging the idea that GLP-1 response is weaker in this group. It's a big move for metabolic health management.
The Lancet published findings from the TRIUMPH-2 study on retatrutide, a triple-agonist (GLP-1, GIP, glucagon) for people with obesity and type 2 diabetes. The phase 3 trial showed superior weight-lowering effects, challenging the idea that GLP-1 response is weaker in this group. It's a big move for metabolic health management.
The architecture take
For a long time, the thinking went like this: if you had type 2 diabetes, GLP-1 drugs wouldn't hit the weight loss numbers they did for someone without diabetes. This new TRIUMPH-2 study on retatrutide just flipped that on its head. This triple-action peptide (GLP-1, GIP, glucagon) showed impressive weight reduction in patients already managing diabetes, closing that perceived gap.
What this means for your body is a more potent tool to dial down blood sugar and body fat at the same time, hitting multiple metabolic pathways. I always thought that 'less effective for diabetics' narrative felt too simple. This trial hints that we've just been waiting for the right blend of hormones to get the job done. Watch for how quickly this one moves through regulatory bodies and how it might change the conversation around diabetes and obesity as distinct, or deeply intertwined, metabolic states. The next question is always about the long game, of course.